Compare Enveric Biosciences Inc (ENVB) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Vanguard Total World Stock Index Fund ETF trades at $159.34 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 14955.9× Enveric Biosciences Inc's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| ENVB | VT | |
|---|---|---|
Market Cap | $6.80M | $101.70B |
Volume | 64,867 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $162.39 |
52-Week Low | $1.27 | $134.19 |
Typical Hold Time | 14 Days | 53 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
VT trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish bias in moving averages while oscillators remain neutral. The ETF maintains strong global diversification with over 9,700 stocks across developed and emerging markets. Recent news highlights VT's competitive positioning against international-focused ETFs, with Seeking Alpha maintaining a Buy rating and targeting 6-10% returns over the next 6-12 months.
VT offers comprehensive global equity exposure with a low 0.06% expense ratio, though key financial ratios remain unavailable. The outlook remains positive for long-term diversification, with risks including currency fluctuations and geopolitical tensions. Institutional activity shows mixed signals with both position increases and decreases reported in recent quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
